← Back

PharmaResources (Shanghai) Co. Ltd. A

PharmaResources (Shanghai) Co., Ltd., together with its subsidiaries, operates as a one-stop integrated service provider for new drug research, development, and commercial manufacturing to pharmaceutical and biotechnology companies in China and internationally. The company offers contract research organization (CRO), contract manufacturing organization (CMO), contract development and manufacturing organization (CDMO), and commercial manufacturing services for small molecule drugs. It is also involved in the research, development, and customized/commercial production of active pharmaceutical ingredients and key intermediates, including ticagrelor, oxiracetam, l-carnitine, velpatasvir, peramivir trihydrate, huperzine A, and vitamin K2, as well as design, screening, and optimization of hit compounds and lead compounds; conducting of structural improvements; and provision of preliminary safety screening to obtain candidate compounds with outstanding drug properties and intellectual property rights. In addition, the company provides medicinal chemistry, process research and development, pharmaceutical research, molecular building blocks, and pharmacokinetics services. Further, it engages in pharmaceutical technology research and development activities. PharmaResources (Shanghai) Co., Ltd. was founded in 2007 and is based in Shanghai, China.

Price · split & dividend adjusted
News & notes moving 301230.CS
Biotech & Genomic Medicine

昭衍新薬が5日で3回目のストップ高、実験用サルの価格が1年で倍に

実験動物関連株が引き続き活況で、昭衍新薬は本日ストップ高となり、5日で3回目のストップ高を記録した。同社は2026年上半期の親会社株主に帰属する純利益が6億元から9億元となり、前年同期比884.9%から1377.4%の増加を見込んでいる。業績急拡大の主因は、実験用サルの市場価格上昇と自然成長による価値増加だ。中国政府采购網のデータによると、カニクイザルの購入単価は2025年5月の9万2000元から2026年6月には19万元に上昇した。浙商証券のリポートは、国内の実験用サルの年間需要が4万頭を突破し、1万頭近くの供給不足が生じていると指摘。2026年から2028年にかけての需給ギャップは少なくとも1万5000頭から2万頭に達し、サル価格は高止まりする可能性があるとしている。
央广财经·42d続きを読む ▾